Ravi A. Madan, MD, Discusses the Significance of the PEACE-1 Trial With Docetaxel, Abiraterone, ADT, and Radiotherapy in mCSPC

Video

Ravi A. Madan, MD, discusses the potential impact of docetaxel, abiraterone acetate, androgen deprivation therapy, and radiotherapy on patients with metastatic castration-sensitive prostate cancer.

At the 2021 European Society for Medical Oncology Annual Congress, CancerNetwork® spoke with Ravi A. Madan, MD, clinical director of the genitourinary malignancies branch at the Center for Cancer Research, National Cancer Institute, about the significance of the phase 3 PEACE-1 trial (NCT01957436) with docetaxel, abiraterone acetate (Zytiga), androgen deprivation therapy (ADT), and radiotherapy for the treatment of metastatic castration-sensitive prostate cancer (mCSPC).

Madan explained how the study’s regimen yielded promising data and may lead to superior outcomes in patients with mCSPC. However, he explained that investigators will need to ensure that the regimen is feasible so more patients are able to receive benefit from treatment.

Transcript:

[At] this year’s meeting, we had some very interesting data presented in the PEACE-1 trial that highlighted the potential of docetaxel and abiraterone in combination with ADT, and potentially radiation, to have superior outcomes in [mCSPC]. This represents the first data that have shown that combination of chemotherapy and an anti-androgen like abiraterone can improve outcomes [in this setting]. We have to figure out how we can get those data to our patients and make it feasible for more people to benefit.

Reference

Fizazi K, Galceran JC, Foulon S, et al. A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1. Ann Oncol. 2021;32(suppl 5):S1283-S1346. doi:10.1016/annonc/annonc741

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content